NCT01856543

Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation

Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 143 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out if the effect of mometasone furoate is any different from Eucerin in decreasing the severity of redness of the skin during irradiation, preventing the skin from peeling, or reducing the amount of irritation the patient reports during treatment.

Conditions

• Invasive Breast Cancer

Interventions

Type	Name	Description
OTHER	Eucerin
OTHER	Mometasone Furoate 0.1%

Timeline

• Start date: 2013-05-01
• Primary completion: 2017-01-01
• Completion: 2017-01-01
• First posted: 2013-05-17
• Last updated: 2019-10-03
• Results posted: 2019-10-03

Locations

6 sites across 1 country: United States